Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Zymeworks Inc. (ZYME) Market Cap & Valuation Ratios

Zymeworks Inc. (ZYME) has a market cap of $2.0B and a price-to-sales ratio of 53.9, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ZYMEZymeworks Inc.Follow ZYME — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
2.0B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
ZYME2.0—49.1—-6.0%-70%-419%—
VCEL2.290.56.664.72.8%+23%6%7%
HRMY2.111.71.76.216.9%+24%24%35%
BHVN2.1——————-437%
IMNM2.0———-10.7%——-125%
VERA2.0——————-90%
RXRX2.0—26.4——-15%—-136%
MRVI1.9—9.5—-1.9%-5%-56%-41%
SEPN1.9—15.3—5.6%—-44%-18%
SRPT1.9—1.0—4.4%-20%-7%-8%
XNCR1.9—15.2—-11.1%-29%-206%-34%
Median of these 1051.19.535.52.8%-10%-26%-37%

; EV/Sales 49.1 vs. 9.5.

Growth vs. price

each dot a company · hover or tap for values

Zymeworks Inc. — questions

What is Zymeworks Inc.'s market cap?
$2.0B.
What is Zymeworks Inc.'s price-to-sales ratio?
53.9.

Every figure on this page comes from Zymeworks Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.